Genetic Testing to Understand and Address Renal Disease Disparities

Completed · Not applicable

Conditions studied: Hypertension, Chronic Kidney Disease, Genomics

In brief

In this genomic medicine implementation pilot project, the investigators aim to conduct a randomized trial in a network of community health centers and primary care facilities to study processes, effects and challenges of incorporating information for apolipoprotein L1 (APOL1)-attributable genetic risk for end stage kidney disease in patients of African ancestry with hypertension .

Key facts

Study ID

NCT02234063

Run by

Icahn School of Medicine at Mount Sinai

People needed

2052

Starts

2014-11-01

Expected to finish

2018-01-12

Last updated by the study team

2020-10-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Ages18-65
• Self-identifies as Black/African American
• History of hypertension
• Patient at a participating site

You may not qualify if…

• History of Chronic Kidney Disease
• History of Diabetes
• Pregnant
• Cognitively impaired/unable to provide consent
• Terminally ill
• Planning to leave area of study permanently during the one year study period

Where it is running

• Institute for Family Health — New York, New York, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.